Faricimab for Age-Related Macular Degeneration
(CONSTANCE Trial)
Trial Summary
What is the purpose of this trial?
This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatment-naïve in the study eye.
Research Team
Clinical Trials
Principal Investigator
Hoffmann-La Roche
Eligibility Criteria
This trial is for adults with a specific eye condition called neovascular age-related macular degeneration (nAMD) who haven't had previous treatments. They should be able to see at certain levels, have clear eyes for imaging, agree to follow contraception rules, and be generally healthy.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive intravitreal 6-mg faricimab administered at up to 24-week intervals
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Faricimab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hoffmann-La Roche
Lead Sponsor
Dr. Levi Garraway
Hoffmann-La Roche
Chief Medical Officer since 2019
MD from the University of Basel
Dr. Thomas Schinecker
Hoffmann-La Roche
Chief Executive Officer since 2023
PhD in Molecular Biology from New York University